CAMP4 Therapeutics Corporation announced the pricing of its initial public offering (IPO) on October 10, 2024. The company offered 6,820,000 shares of its common stock at an initial public offering price of $11.00 per share. This offering is expected to generate gross proceeds of approximately $75.0 million for the clinical-stage biotechnology company.
The common stock of CAMP4 was anticipated to commence trading on the Nasdaq Global Market on October 11, 2024, under the ticker symbol "CAMP". The offering was projected to officially close on October 15, 2024, subject to the fulfillment of customary closing conditions.
Furthermore, CAMP4 granted the underwriters a 30-day option to purchase up to an additional 1,023,000 shares of common stock at the initial public offering price. J.P. Morgan, Leerink Partners, Piper Sandler, and William Blair are serving as joint book-running managers for this offering.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.